Trial Profile
A Phase I, Open-label Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Doses of SH-1028 Tablets in Patients With Advanced Non-small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Feb 2023
Price :
$35
*
At a glance
- Drugs Oritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Nanjing Sanhome Pharmaceutical
- 22 Feb 2023 Results(Data cut off on December 31, 2020, n=20) assessing clinical safety, preliminary efficacy, and pharmacokinetic SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients published in the Cancer
- 25 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 01 Aug 2018 New trial record